XML 105 R17.htm IDEA: XBRL DOCUMENT
v3.25.1

DERIVATIVE FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS | 9 Months Ended | 12 Months Ended
--- | --- | ---
Mar. 31, 2025 | Jun. 30, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract] |  |
DERIVATIVE FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS | NOTE 11 - DERIVATIVE FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS Derivative Financial Instruments: The Company applies the provisions of ASC 815-40, Contracts in Entity’s Own Equity, under which convertible instruments and warrants, which contain terms that protect holders from declines in the stock price (reset provisions), may not be exempt from derivative accounting treatment. As a result, warrants and embedded conversion options in convertible debt are recorded as a liability and are revalued at fair value at each reporting date. If the fair value of the warrants exceeds the face value of the related debt, the excess is recorded as change in fair value in operations on the issuance date. The Company had $211,650 (7 notes) and $110,500 (3 notes) of convertible debt, which were treated as derivative instruments outstanding at March 31, 2025 and June 30, 2024, respectively. The Company calculates the estimated fair values of the liabilities for derivative instruments using the Binomial Trees Method. The closing price of the Company’s common stock at March 31, 2025, the last trading day of the period ended March 31, 2025, was $5.50. The volatility, expected remaining term and risk-free interest rates used to estimate the fair value of derivative liabilities at March 31, 2025 are indicated in the table that follows. The expected term is equal to the remaining term of the warrants or convertible instruments and the risk-free rate is based upon rates for treasury securities with the same term. PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS March 31, 2025 (Unaudited) Convertible Debt SCHEDULE OF FAIR VALUE MEASUREMENTS, RECURRING AND NONRECURRING, VALUATION TECHNIQUES
|  | Initial Valuations (on new derivative instruments entered into during the three months ended March 31, 2025) |  |  | March 31, 2025 |
Volatility |  |  | 344-368 | % |  |  | 344 | %
Expected Remaining Term (in years) |  |  | 0.66 |  |  |  | 0.01 - 0.62 |
Risk Free Interest Rate |  |  | 4.25-4.26 | % |  |  | 4.23-4.38 | %
Expected dividend yield |  |  | None |  |  |  | None |
Fair Value Measurements: The Company measures and reports at fair value the liability for derivative instruments. The fair value of liabilities for price adjustable warrants and embedded conversion options have been recorded as determined utilizing the Binomial Trees model. The following tables summarize the Company’s financial assets and liabilities measured at fair value on a recurring basis as of March 31, 2025 and June 30, 2024: SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS
|  | Balance at March 31, 2025 |  |  | Quoted Prices in Active Markets for Identical Assets |  |  | Significant Other Observable Inputs |  |  | Significant Unobservable Inputs |
|  |  |  |  | (Level 1) |  |  | (Level 2) |  |  | (Level 3) |
Embedded conversion option liabilities |  | $ | 191,770 |  |  | $ | — |  |  | $ | — |  |  | $ | 191,770 |
Total |  | $ | 191,770 |  |  | $ | — |  |  | $ | — |  |  | $ | 191,770 |
|  | Balance at June 30, 2024 |  |  | Quoted Prices in Active Markets for Identical Assets |  |  | Significant Other Observable Inputs |  |  | Significant Unobservable Inputs |
|  |  |  |  | (Level 1) |  |  | (Level 2) |  |  | (Level 3) |
Embedded conversion option liabilities |  | $ | 133,886 |  |  | $ | — |  |  | $ | — |  |  | $ | 133,886 |
Total |  | $ | 133,886 |  |  | $ | — |  |  | $ | — |  |  | $ | 133,886 |
The following is a roll forward for the nine months ended March 31, 2025 of the fair value liability of price adjustable derivative instruments: SCHEDULE OF DERIVATIVE LIABILITIES AT FAIR VALUE
|  | Fair Value of |
|  | Liability for |
|  | Derivative |
|  | Instruments |
Balance at June 30, 2024 |  | $ | 133,886 |
Initial fair value of embedded conversion option derivative liability recorded as debt discount |  |  | 150,000 |
Initial fair value of embedded conversion option derivative liability recorded as derivative expense |  |  | 95,012 |
Reduction of derivative liability upon debt conversion |  |  | (73,641 | )
Change in fair value included in statements of operations |  |  | (113,487 | )
Balance at March 31, 2025 |  | $ | 191,770 |
PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS March 31, 2025 (Unaudited) | NOTE 12 - DERIVATIVE FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS Derivative Financial Instruments: The Company applies the provisions of ASC 815-40, Contracts in Entity’s Own Equity, under which convertible instruments and warrants, which contain terms that protect holders from declines in the stock price (reset provisions), may not be exempt from derivative accounting treatment. As a result, warrants and embedded conversion options in convertible debt are recorded as a liability and are revalued at fair value at each reporting date. If the fair value of the warrants exceeds the face value of the related debt, the excess is recorded as change in fair value in operations on the issuance date. The Company had $110,500 (3 notes) and $75,300 (2 notes) of convertible debt, which were treated as derivative instruments outstanding at June 30, 2024 and 2023, respectively. The Company calculates the estimated fair values of the liabilities for derivative instruments using the Binomial Trees Method. The closing price of the Company’s common stock at June 28, 2024, the last trading day of the period ended June 30, 2024, was $78 per share. The volatility, expected remaining term, and risk-free interest rates used to estimate the fair value of derivative liabilities at June 30, 2024 are indicated in the table that follows. The expected term is equal to the remaining term of the warrants or convertible instruments and the risk-free rate is based upon rates for treasury securities with the same term. Convertible Debt SCHEDULE OF FAIR VALUE MEASUREMENTS, RECURRING AND NONRECURRING, VALUATION TECHNIQUES
|  | Initial Valuations (on new derivative instruments entered into during the year ended June 30, 2024)
Volatility |  |  | 323.40 – 333.45 | %
Expected Remaining Term (in years) |  |  | 0.50 |
Risk Free Interest Rate |  |  | 5.42 - 5.55 | %
Expected dividend yield |  |  | None |
|  | June 30, 2024 |  | June 30, 2023
Volatility |  |  | 323.40 | % |  |  | 334.56 | %
Expected remaining term |  |  | 0.01 - 0.28 |  |  |  | 0.01 - 0.73 |
Risk-free interest rate |  |  | 5.45 - 5.47 | % |  |  | 5.24 | %
Expected dividend yield |  |  | None |  |  |  | None |
Fair Value Measurements: The Company measures and reports at fair value the liability for derivative instruments. The fair value liabilities for price adjustable warrants and embedded conversion options have been recorded as determined utilizing the Binomial Trees model. The following tables summarize the Company’s financial assets and liabilities measured at fair value on a recurring basis as of June 30, 2024: SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS
|  | Balance at June 30, 2024 |  | Quoted Prices in Active Markets for Identical Assets |  | Significant Other Observable Inputs |  | Significant Unobservable Inputs
|  |  |  | (Level 1) |  | (Level 2) |  | (Level 3)
Embedded conversion option liabilities |  | $ | 133,886 |  |  | $ | — |  |  | $ | — |  |  | $ | 133,886 |
Total |  | $ | 133,886 |  |  | $ | — |  |  | $ | — |  |  | $ | 133,886 |
The following tables summarize the Company’s financial assets and liabilities measured at fair value on a recurring basis as of June 30, 2023:
|  | Balance at June 30, 2023 |  | Quoted Prices in Active Markets for Identical Assets |  | Significant Other Observable Inputs |  | Significant Unobservable Inputs
|  |  |  | (Level 1) |  | (Level 2) |  | (Level 3)
Embedded conversion option liabilities |  | $ | 423,209 |  |  | $ | — |  |  | $ | — |  |  | $ | 423,209 |
Total |  | $ | 423,209 |  |  | $ | — |  |  | $ | — |  |  | $ | 423,209 |
PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2024 and 2023 The following is a roll forward for the years ended June 30, 2024 and 2023 of the fair value liability of price adjustable derivative instruments: SCHEDULE OF DERIVATIVE LIABILITIES AT FAIR VALUE
|  | Fair Value of
|  | Liability for
|  | Derivative
|  | Instruments
Balance at June 30, 2022 |  | $ | 151,262 |
Initial fair value of embedded conversion option derivative liability recorded as debt discount |  |  | 93,668 |
Gain on debt extinguishment |  |  | (352,051 | )
Change in fair value included in statements of operations |  |  | 530,330 |
Balance at June 30, 2023 |  |  | 423,209 |
Initial fair value of embedded conversion option derivative liability recorded as debt discount |  |  | 150,000 |
Initial fair value of embedded conversion option derivative liability recorded as derivative expense |  |  | 141,012 |
Gain on debt extinguishment |  |  | (263,798 | )
Change in fair value included in statements of operations |  |  | (316,537 | )
Balance at June 30, 2024 |  | $ | 133,886 |

X
- References No definition available. + Details
Name: | us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-5 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-5C Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 815 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/815/tableOfContent + Details
Name: | us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration